| 3/16/2022 |
Gluco Spark - Glucosemeter Review |
apsense.com |
Gluco Spark - Glucosemeter[Sensa Core] Committed to High Quality DiagnosticsGluco Spark is India's first, next-generation, highly advanced ultra-low volume glucose monitoring system available at affordable prices. This glucometer works on advanced biosensor technology Recommended FeaturesLearn more about Gluco Spark - Glucosemeter»- Principle - Advanced Biosensor Technology - Reading Time - 5 Seconds- Sample Volume - 0.5 microliter- Memory - 1000 Readings- Battery - Lasts Upto 1000 TestsReview on Gluco Spark - Glucosemeter ... |
| 3/2/2022 |
GRIP Molecular Announces BLUE KNIGHT‚Ñ¢ Acceptance |
PR Newswire |
... Knight , GRIP will receive fee assistance towards its JLABS residency at JPOD @ Boston , located at the Cambridge Innovation Center's (CIC) location in Kendall Square, Cambridge Massachusetts .GRIP is developing a novel graphene-based electronic biosensor technology that aims to provide rapid, simultaneous, lab-grade accuracy detection of an array of infectious diseases, anytime, anywhere, by any user. Using GRIP's disposable cartridge and a standard cell phone, the device will provide ... |
| 3/2/2022 |
GRIP Molecular Announces BLUE KNIGHT‚Ñ¢ Acceptance |
PR Newswire |
... Knight , GRIP will receive fee assistance towards its JLABS residency at JPOD @ Boston , located at the Cambridge Innovation Center's (CIC) location in Kendall Square, Cambridge Massachusetts .GRIP is developing a novel graphene-based electronic biosensor technology that aims to provide rapid, simultaneous, lab-grade accuracy detection of an array of infectious diseases, anytime, anywhere, by any user. Using GRIP's disposable cartridge and a standard cell phone, the device will provide ... |
| 3/2/2022 |
Optical nano-biosensor enables rapid and quantitative serological testing of COVID-19 |
nanowerk.com |
... samples, provided by the Vall d'Hebron University Hospital and the Hospital Clínic of Barcelona–IDIBAPS during the first months of COVID-19 pandemic, was performed to prove the efficacy and reliability of this biosensor technology . In particular, 120 samples of serum were used, of which 100 from confirmed COVID-19 positive patients and 20 negative ones (collected prior to the outbreak of the pandemic). Comparative analyses with standard techniques ... |
| 1/31/2022 |
The Global Biosensors Market is expected to grow by $ 10.85 |
Globe Newswire |
... around 25 vendors.The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the advances in biosensor technology and the advantages of biosensors in drug analysis. In addition, advances in biosensor technology is anticipated to boost the growth of the market as well.The biosensors market analysis includes the product segment and ... |
| 1/10/2022 |
VitalConnect Announces Closure of $39 Million Round of Growth Financing |
Business Wire |
SAN JOSE, Calif.--(BUSINESS WIRE)--Jan 10, 2022--VitalConnect ®, Inc. , a leader in remote and in-hospital wearable biosensor technology , today announced the completion of a $39 million round of financing, funded by EW Healthcare Partners in addition to other new and existing VitalConnect investors. Additionally, the company announced that Robert S. White, Operating Partner at EW Healthcare Partners has joined its Board of Directors.The latest round of ... |
| 1/10/2022 |
VitalConnect Announces Closure of $39 Million Round of Growth Financing | Business | Maryville Daily Forum |
maryvilleforum.com |
SAN JOSE, Calif.--(BUSINESS WIRE)--Jan 10, 2022--VitalConnect ®, Inc. , a leader in remote and in-hospital wearable biosensor technology , today announced the completion of a $39 million round of financing, funded by EW Healthcare Partners in addition to other new and existing VitalConnect investors. Additionally, the company announced that Robert S. White, Operating Partner at EW Healthcare Partners has joined its Board of Directors.The latest round of ... |
| 1/10/2022 |
VitalConnect Announces Closure of $39 Million Round of Growth Financing | News | bakersfield.com |
bakersfield.com |
SAN JOSE, Calif.--(BUSINESS WIRE)--Jan 10, 2022--VitalConnect ®, Inc. , a leader in remote and in-hospital wearable biosensor technology , today announced the completion of a $39 million round of financing, funded by EW Healthcare Partners in addition to other new and existing VitalConnect investors. Additionally, the company announced that Robert S. White, Operating Partner at EW Healthcare Partners has joined its Board of Directors.The latest round of ... |
| 1/10/2022 |
VitalConnect Announces Closure of $39 Million Round of Growth Financing | Business & Finance |
citizentribune.com |
SAN JOSE, Calif.--(BUSINESS WIRE)--Jan 10, 2022--VitalConnect ®, Inc. , a leader in remote and in-hospital wearable biosensor technology , today announced the completion of a $39 million round of financing, funded by EW Healthcare Partners in addition to other new and existing VitalConnect investors. Additionally, the company announced that Robert S. White, Operating Partner at EW Healthcare Partners has joined its Board of Directors.The latest round of ... |
| 1/10/2022 |
VitalConnect Announces Closure of $39 Million Round of Growth Financing |
cardiacvascularnews.com |
Series E Financing led by EW Healthcare Partners with Robert S. White to Join BoardSAN JOSE, Calif.–( BUSINESS WIRE )– VitalConnect®, Inc. , a leader in remote and in-hospital wearable biosensor technology , today announced the completion of a $39 million round of financing, funded by EW Healthcare Partners in addition to other new and existing VitalConnect investors. Additionally, the company announced that Robert S. White, Operating Partner ... |
| 12/20/2021 |
New biosensors measure toxic drugs in cancer, arthritis, and organ transplant patients |
yerepouni-news.com |
... lab equipment and new point-of-care devices.“Proteins are at the core of a US$70-billion-dollar global diagnostic market that relies heavily on central lab processing,” Professor Alexandrov said.“Our biosensor technology will enable tests like therapeutic drug monitoring on less sophisticated equipment that you are more likely to find in small, regional or remote labs and hospitals.”Future tests may also require smaller biological ... |
| 12/20/2021 |
Biosensors Measure Toxic Drugs in Cancer, Arthritis, Transplant Patients |
medindia.net |
... lab equipment and new point-of-care devices. "Proteins are at the core of a US$70-billion-dollar global diagnostic market that relies heavily on central lab processing," Professor Alexandrov said. Advertisement "Our biosensor technology will enable tests like therapeutic drug monitoring on less sophisticated equipment that you are more likely to find in small, regional or remote labs and hospitals." Future tests may also require smaller biological samples ... |
| 12/20/2021 |
New Biosensors Precisely Monitor Drug Levels in Serum |
clinicalomics.com |
Researchers have created biosensors that can accurately measure levels of cancer, arthritis, and organ transplant drugs in blood samples.“Our biosensor technology will enable tests like therapeutic drug monitoring on less sophisticated equipment,” said senior author Professor Kirill Alexandrov, of the QUT Centre for Genomics and Personalised Health. He believes these new biosensors could disrupt the $70 billion global diagnostic market by allowing more personalized treatment on cheaper lab ... |
| 12/19/2021 |
New biosensors measure toxic drugs in cancer, arthritis, and organ transplant patients |
bioengineer.org |
... lab equipment and new point-of-care devices.“Proteins are at the core of a US$70-billion-dollar global diagnostic market that relies heavily on central lab processing,” Professor Alexandrov said.“Our biosensor technology will enable tests like therapeutic drug monitoring on less sophisticated equipment that you are more likely to find in small, regional or remote labs and hospitals.”Future tests may also require smaller biological ... |
| 12/19/2021 |
New biosensors measure toxic drugs in cancer, arthritis, and organ transplant patients |
eurekalert.org |
... lab equipment and new point-of-care devices.“Proteins are at the core of a US$70-billion-dollar global diagnostic market that relies heavily on central lab processing,” Professor Alexandrov said.“Our biosensor technology will enable tests like therapeutic drug monitoring on less sophisticated equipment that you are more likely to find in small, regional or remote labs and hospitals.”Future tests may also require smaller biological ... |
| 10/13/2021 |
BioIntelliSense Honored by Goldman Sachs for Entrepreneurship |
Globe Newswire |
... 100 entrepreneurs from multiple industries to be honored at the two-day event. Dr. Mault is the Founder and Chief Executive Officer of BioIntelliSense, a company based in Denver, Colorado delivering breakthrough medical-grade biosensor technology with advanced clinical intelligence for scalable remote patient monitoring. Previously, Dr. Mault served as Senior Vice President and Chief Medical Officer of Qualcomm Life; Medical Director, Health Solutions Group at Microsoft; and CEO of ... |
| 9/24/2021 |
Mecwins Developing 'Highly Sensitive' Plasmonic Testing Tech for Laboratories, Point of Care |
360dx.com |
... is developing in vitro diagnostic testing technology for use in laboratories and decentralized settings to detect analyte concentrations measured in femtograms per milliliter, or 1,000 times more sensitive than widely available laboratory ELISAs. The biosensor technology being developed by the company, a spinout of the Spanish National Research Council's CSIC Micro and Nanotechnology Institute, is called Avac and uses plasmonic resonance for detection in standard sandwich immunoassays. Avac enables multiplex ... |
| 9/15/2021 |
VitalConnect Introduces New VistaCenter With Powerful Workflow Capabilities to Maximize Clinical Efficiency |
hmpgloballearningnetwork.com |
Market-leading workflow with historical and real-time patient data monitoring allows exceptional ease of patient managementSAN JOSE, Calif. – VitalConnect ® , Inc. , a leader in remote and in-hospital wearable biosensor technology , announced it has launched its new version of VistaCenter for cardiac and remote patient monitoring. This new version brings market-leading patient management and monitoring tools such as simplified patient intake, live patient census views, custom ... |
| 9/14/2021 |
VitalConnect Introduces New VistaCenter With Powerful Workflow Capabilities to Maximize Clinical Efficiency | Financial Buzz |
financialbuzz.com |
VitalConnect ® , Inc. , a leader in remote and in-hospital wearable biosensor technology , today announced it has launched its new version of VistaCenter for cardiac and remote patient monitoring. This new version brings market-leading patient management and monitoring tools such as simplified patient intake, live patient census views, custom notification profiles and report delivery—all designed to streamline workflow and make patient management easier and less time-intensive for ... |
| 9/13/2021 |
iRhythm gets back on beat, tapping former Dexcom exec as CEO |
FierceBiotech |
... and president of the San Francisco-based company, effective Oct. 4. At that time, he’ll also join iRhythm’s board of directors.Blackford comes to iRhythm with a wealth of experience in both biosensor technology and the medical device market as a whole. Most recently, he spent four years at Dexcom, maker of under-the-skin continuous glucose monitoring technology. At Dexcom, he served first as chief financial officer ... |